Recent evidence suggests that the current acelluar Bordetella pertussis vaccine (aP) protects against whooping cough disease, but not against secondary transmission of the B. pertussis bacterium. In other words, the aP vaccine allows for asymptomatic B. pertussis infections, allowing individuals to unknowingly transmit infection to other vaccinated and un-vaccinated individuals. Importantly, this includes infants too young to be vaccinated, where the mortality rate from whooping cough is significantly higher than for older children and adults. Until an improved vaccine is developed, an interim strategy needs to be deployed in order to minimize B. pertussis transmission, lower incidence of whooping cough, and prevent unnecessary infant mortality. This study explores the possibility of incorporating a single dose of the highly effective, yet side-effect-prone, whole-cell B. pertussis vaccine (wP) in current vaccination strategies. Using a dynamic transmission model this study finds that a vaccination strategy combining aP and wP vaccines: reduces rates of B. pertussis infections 95% over the continued use of the aP vaccine alone, and decreases infections 96% in infants; it also predicts significant decreases in infant death rates due to whooping cough and whooping cough complications, and marginally increases rates of vaccine-side effects in infants. The model also predicts a significant overall cost savings with a switch to a combined strategy. Cost savings and utilitarian reasoning alone are not sufficient to justify a switch to a combined strategy. But the ethical responsibility of public health officials to effectively minimize disease, morbidity, and death obliges a switch. This presentation will concentrate on a detailed ethical evaluation focused on risk analysis from the perspective of both the healthcare providers and parents and children receiving the vaccine.